ReviewBioactive materials2026
Toward multifunctional nanoplatforms based on layered double hydroxides (LDHs) for cancer therapy: From structural design to application.
Review in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in research on layered double hydroxides for biomedical applications.Smart molecules : open access · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Layered double hydroxides (LDHs), known as anionic clays structured from metal hydroxide layers bearing positive charges and embedded anions are emerging as valuable tools in the field of cancer treatment. Owing to their inherent features such as extensive surface area, adjustable structure, ion-exchange potential, and compatibility with biological systems, these materials are well-suited for encapsulating and delivering various therapeutic agents including chemotherapeutic drugs, gene-based treatments, photosensitizers (PSs), and immune-modulating compounds in a controlled manner. This review offers an in-depth analysis of the latest developments in the design, preparation, and modification of LDHs for cancer-related applications with a special focus on their use in localized therapeutic delivery, gene transfer strategies, and multimodal therapeutic approaches. A novel dimension of LDH nanotechnology lies in its evolution from passive drug carriers to multifunctional theranostic systems capable of real-time imaging, environmental responsiveness, and multi-modal treatment delivery. Emerging innovations include synergistic photothermal-chemodynamic therapy, LDH-mediated immunotherapy, and CRISPR-Cas9 gene editing facilitated by the pH-sensitive and protective nature of LDHs. Additionally, hybridization with other nanomaterials and integration with AI-guided design and wearable biosensor technologies are opening new frontiers in personalized cancer care. Despite challenges such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.